statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Marker Therapeutics (NASDAQ:MRKR)  Shares Down 2.7%

Marker Therapeutics, Inc. (NASDAQ:MRKR - Get Free Report)'s share price traded down 2.7% on Friday . The company traded as low as $4.66 and last traded at $4.75. 31,276 shares traded hands during...

Marker Therapeutics Advances in Immuno-Oncology

Marker Therapeutics (MRKR) has released an update. Marker Therapeutics has announced significant strides in its immuno-oncology programs, including...

Marker Therapeutics Reports Year-End 2023 Corporate and Financial Results

Lead program in patients with lymphoma demonstrated preliminary safety and efficacy results with sustained complete response in first study participant treated with MT-601 (Neldaleucel) following CAR...

Marker Therapeutics to Present at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference

HOUSTON, March 22, 2024 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies...

Marker Therapeutics Ends Stock Sale Deal with LPC

An announcement from Marker Therapeutics Inc (MRKR) is now available. Marker Therapeutics, Inc. has terminated its stock sale agreement with Lincol...

Marker Therapeutics Receives Approval from United States Adopted Name (USAN) Council and International Nonproprietary Names (INN) Expert Committee for  Neldaleucel  as Nonproprietary Name for MT-601

HOUSTON, Jan. 22, 2024 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for...

Marker Therapeutics (NASDAQ:MRKR) Shares Up 0.4%

Marker Therapeutics, Inc. (NASDAQ:MRKR  Get Free Report)s stock price shot up 0.4% on Tuesday . The company traded as high as $5.00 and last traded at $4.96. 28,057 shares were traded...

Cancer Cell Therapy Focused Marker Therapeutics Announces Pipeline Prioritization

Marker Therapeutics Inc (NASDAQ: MRKR) announced it is restructuring its clinical programs and strategic prioritization of its multi-tumor associated antigen (multiTAA)-specific T cell product...

Marker Therapeutics Announces Clinical Program Updates and Pipeline Prioritization

Strategic prioritization of clinical programs with focus on MT-601 in patients with lymphoma MultiTAA-specific T cell therapies demonstrate clinical safety and positive clinical data across multiple...

Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company, which engages in the development and commercialization of novel cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company was founded on October 22, 1991 and is headquartered in Houston, TX.

Volume	15,692.00
52-Wk High	$8.20
52-Wk Low	$2.40

MRKR Marker Therapeutics Inc

About

Feed

News

Sentiment

Fundamentals